pancreatic cancer

[Bioscience Reports] Scientists showed that alanine serine cysteine‑preferring transporter 2 (ASCT2) expression was significantly higher in pancreatic cancer than in normal pancreatic duct cells and pancreas.

[Cellular and Molecular Gastroenterology and Hepatology] Scientists discovered that non-cell autonomous oncogenic KRAS signaling reprogramed pancreatic fibroblasts, activating an inflammatory gene expression program.

[Scientific Reports] Researchers utilized high resolution flow cytometry to detect EVs in the plasma of patients with pancreatic ductal adenocarcinoma (PDAC) and in the supernatants of PDAC and healthy control pancreatic organoid cultures.

[Drug Discovery Today] Nanoparticle drug delivery systems have increased the efficacy of chemotherapeutics by improving the targeting ability of drugs to the tumor site, while also decreasing the risk of local and systemic toxicity.

[Journal of Liposome Research] Investigators developed the liposomal formulation, by ether injection method, comprising erlotinib, a tyrosine kinase EGFR inhibitor, proposed to be targeted through enhanced permeability and retention effect effect against pancreatic cancer.

[RenovoRx, Inc.] RenovoRx, Inc. announced enrollment of its first patient at one of its newest clinical sites, Columbia University, in its ongoing TIGeR-PaC Phase III clinical trial to evaluate the company’s therapy platform RenovoTAMP™ as a potential treatment option for locally advanced pancreatic cancer.